Physician profile
Barbara White
NPI 1750174595
$1,446.46
in general payments reported to CMS, 2019-2025
20 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 92% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $200.20 | 2025 | Minimed 780g |
| Abbvie INC. | $164.76 | 2025 | |
| Insulet Corporation | $150.00 | 2025 | Omnipod |
| Novo Nordisk INC | $142.82 | 2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $125.00 | 2025 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $124.63 | 2025 | Austedo Xr |
| Radius Health, INC. | $108.13 | 2025 | Tymlos |
| Abbott Laboratories | $70.52 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $51.05 | 2025 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $43.90 | 2025 | |
| Xeris Pharmaceuticals, INC. | $41.73 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $37.03 | 2025 | Korlym |
| Madrigal Pharmaceuticals | $35.29 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $30.64 | 2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $27.68 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $23.54 | 2025 | Isturisa |
| Sequel Med Tech, LLC | $18.94 | 2025 | Twiist |
| Medicure Pharma INC. | $18.38 | 2025 | Zypitamag |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.10 | 2025 | Jardiance |
| Sandoz INC. | $15.12 | 2025 | Jubbonti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.